tiprankstipranks
Advertisement
Advertisement
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
PremiumCompany AnnouncementsAnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
2M ago
AnaptysBio price target raised to $76 from $60 at UBS
Premium
The Fly
AnaptysBio price target raised to $76 from $60 at UBS
2M ago
AnaptysBio price target raised to $75 from $63 at Barclays
Premium
The Fly
AnaptysBio price target raised to $75 from $63 at Barclays
2M ago
AnaptysBio price target raised to $85 from $66 at Leerink
PremiumThe FlyAnaptysBio price target raised to $85 from $66 at Leerink
2M ago
GSK’s TESARO provides update on AnaptysBio litigation
Premium
The Fly
GSK’s TESARO provides update on AnaptysBio litigation
2M ago
Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
Premium
Ratings
Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
2M ago
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe FlyAnaptysBio price target lowered to $60 from $90 at UBS
2M ago
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
Premium
Company Announcements
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
2M ago
AnaptysBio completes separation of First Tracks Biotherapeutics
Premium
The Fly
AnaptysBio completes separation of First Tracks Biotherapeutics
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100